![An In Depth Review Of Cbd Gummies Relax Nanocraftcbd [OLeO1jbOoaI]](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-8670032-150x150.jpg "An In Depth Review Of Cbd Gummies Relax Nanocraftcbd [OLeO1jbOoaI] 9")
![B+cbd Gummies For Metabolic Balance And Daily Wellness [3s5LqrrZ748]](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-3259579-150x150.jpg "B+cbd Gummies For Metabolic Balance And Daily Wellness [3s5LqrrZ748] 11")
Acute Toxicity of ADB-CHMINACA – Case Series with Pronounced CNS Symptoms
This report presents a series of 16 patients with acute toxicity of ADB-CHMINACA confirmed by analytical testing. Patients exhibited pronounced central nervous system symptoms including panic attacks and seizures. The study highlights the dangers of…
Georgia weighs ban on synthetic hemp, while expanding medical cannabis – AJC.com
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic RegulationSynthetic CannabinoidsMedical…
Emergency Services Respond to Cannabis Sweets Hospitalizations
Cannabis sweets hospitalizations have raised concerns about the dangers of unregulated edibles. Emergency services responded after two individuals required urgent care due to these products. This highlights the clinical challenge of distinguishing…
New Funding to Support SER-252 Trial in Advanced Parkinson’s
The synthetic cannabinoid Parkinsons trial SER-252 targets levodopa-induced dyskinesia in advanced Parkinson's disease. This novel therapeutic approach could improve management of motor symptoms. Ongoing research aims to validate its clinical efficacy…
Older Adults with COPD Were Prescribed Synthetic Cannabinoids More Often—and at Higher Doses—Than Those Without the Disease
Synthetic oral cannabinoid prescribing is significantly more common among older adults with COPD compared to those without the disease. These patients also receive higher doses and longer treatment durations. Understanding these prescribing patterns is…
Synthetic cannabinoids in Mayotte: High-frequency market evolution example
Synthetic cannabinoid receptor agonists (SCRAs) are rapidly evolving in Mayotte, posing unique clinical challenges. Wastewater-based epidemiology reveals high-frequency market changes. Understanding SCRAs is crucial for managing acute health…
MIRA Pharmaceuticals Reports MIRA-55 Avoids CNS Side Effects
Synthetic cannabinoids CNS side effects have limited clinical use of many compounds. MIRA Pharmaceuticals reports MIRA-55 shows no THC- or rimonabant-associated CNS side effects in preclinical studies. This research could advance cannabinoid drug…
CED Regulatory Digest, Since Last Digest, 1 items
Digest covering 1 recent regulatory items.
Many Hemp Intoxicants Contain THC and Synthetic Cannabinoids – NORML Analysis
Unregulated intoxicating hemp products often contain delta-9 THC above legal limits and synthetic cannabinoids. These products pose significant health risks due to unpredictable potency and lack of labeling. Consumers should be aware of the dangers…
Synthetic Cannabinoid Ajulemic Acid Shows Potent Antifibrotic Effects in Systemic Sclerosis Models
Ajulemic acid antifibrotic effects have shown promise in reducing collagen synthesis in systemic sclerosis models. This synthetic cannabinoid activates PPAR-γ to inhibit fibrogenesis. Research supports its potential as a treatment for scleroderma-related…